Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.48 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.48 |
| ▸ | HTR7 | P34969 | 4/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7253587 | 0.92 | HTR2C (0.55) | PRMT5HTR2CHTR2AHTR7PRMT1 | |
| SCHEMBL7253589 | 0.92 | HTR2C (0.55) | PRMT5HTR2CHTR2AHTR7PRMT1 | |
| SCHEMBL7253595 | 0.92 | HTR2C (0.55) | PRMT5HTR2CHTR2AHTR7PRMT1 | |
| SCHEMBL7253257 | 0.80 | HTR2C (0.47) | PRMT5HTR2CHTR2AHTR7PRMT1 | |
| SCHEMBL7253262 | 0.80 | HTR2C (0.47) | PRMT5HTR2CHTR2AHTR7PRMT1 | |
| SCHEMBL8959574 | 0.80 | HTR2C (0.72) | PRMT5HTR2CHTR2AHTR7NTSR1 | |
| SCHEMBL8959569 | 0.80 | HTR2C (0.72) | PRMT5HTR2CHTR2AHTR7NTSR1 | |
| SCHEMBL20618352 | 0.80 | HTR7 (0.51) | PRMT5HTR2CHTR2AHTR7PRMT1 | |
| SCHEMBL24142902 | 0.79 | HTR7 (0.63) | PRMT5HTR2CHTR2AHTR7PRMT1 | |
| SCHEMBL27642179 | 0.78 | HTR2C (0.48) | PRMT5HTR2CHTR2AHTR7PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635639-B2 | Treatment or diagnosis of central nervous system conditions | NPS ALLELIX CORP. (CA) | 2003-10-21 | — | — | US | disclosed |
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | disclosed |
| US-6380242-B1 | FOR DIAGNOSIS AND THERAPY OF CENTRAL NERVOUS SYSTEM CONDITIONS | NPS ALLELIX CORP. (CA) | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | CNR1, CNR2, KCNH1 | HTR2C 127/4885HTR2A 425/4885PRMT5 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.